{
  "success": true,
  "pagesUsed": [
    2,
    4,
    6,
    7,
    16,
    24,
    26,
    27,
    37,
    38,
    40,
    41,
    46,
    54,
    59
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Period",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "Randomization",
        "windowLower": -14,
        "windowUpper": -1
      },
      {
        "id": "timing_2",
        "name": "Treatment Period Duration",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 72,
        "relativeTo": "Randomization",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_3",
        "name": "Dose Escalation Period",
        "type": "Within",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 20,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 140
      },
      {
        "id": "timing_4",
        "name": "Additional Treatment Period for Prediabetes",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 176,
        "relativeTo": "Randomization",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_5",
        "name": "Safety Follow-up Period (First 72 Weeks)",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_6",
        "name": "Safety Follow-up Period (Weeks 72-176)",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 17,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "Office Visit Window (Monthly through Week 24)",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_8",
        "name": "Office Visit Window (Every 12 Weeks after Week 24)",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 12,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_9",
        "name": "Telephone Visit Interval (Starting Week 28)",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_10",
        "name": "Additional 2-Year Period Visit Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "Previous Visit",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_11",
        "name": "Fasting Requirement",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Study Start",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_12",
        "name": "Dose Escalation Increment Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_13",
        "name": "Missed Dose Window",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 72,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 72
      },
      {
        "id": "timing_14",
        "name": "Visit 99 Window",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 72,
        "relativeTo": "Randomization",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_15",
        "name": "Visit 199 Window",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 176,
        "relativeTo": "Randomization",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_16",
        "name": "Dietician Consultation Interval (After Visit 21)",
        "type": "At",
        "unit": "months",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_17",
        "name": "Visit 801 Safety Follow-up",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "End of Treatment",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_18",
        "name": "Visit 802 Safety Follow-up",
        "type": "After",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 17,
        "relativeTo": "End of Treatment",
        "windowLower": 0,
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Prediabetes Status at Randomization",
        "instanceType": "Condition",
        "description": "Participants classified as having prediabetes at randomization continue for additional 104 weeks",
        "text": "Participants classified as having prediabetes at randomization and who remain on study drug through Week 72, will continue follow-up for an additional 104 weeks"
      },
      {
        "id": "cond_2",
        "name": "No Glycemic Evidence of T2DM",
        "instanceType": "Condition",
        "description": "Participants must not have glycemic assessments suggestive of T2DM",
        "text": "Participants who have no glycemic assessments suggestive of T2DM and meet all other applicable inclusion criteria and none of the applicable exclusion criteria"
      },
      {
        "id": "cond_3",
        "name": "Intolerable GI Symptoms",
        "instanceType": "Condition",
        "description": "Condition for dose modification due to gastrointestinal symptoms",
        "text": "Participants who experience intolerable GI symptoms (for example, nausea, vomiting, or diarrhea) at any time during the study"
      },
      {
        "id": "cond_4",
        "name": "Perceived Excessive Weight Loss",
        "instanceType": "Condition",
        "description": "Condition for dose modification during additional 2-year treatment period",
        "text": "Management of participants with perceived excessive weight loss during the additional 2-year treatment period for participants with prediabetes at randomization"
      },
      {
        "id": "cond_5",
        "name": "BMI Target Reached",
        "instanceType": "Condition",
        "description": "Condition for recalculating energy intake",
        "text": "If a BMI ≤22 kg/m2 is reached, the recommended energy intake should be recalculated with no kcal deficit for the remainder of the trial"
      },
      {
        "id": "cond_6",
        "name": "Temporary Drug Interruption Eligibility",
        "instanceType": "Condition",
        "description": "Condition for allowing temporary study drug interruption",
        "text": "A temporary interruption of study drug for 1 dose is permitted, provided the participant has taken the last 3 weekly doses"
      },
      {
        "id": "cond_7",
        "name": "Pregnancy",
        "instanceType": "Condition",
        "description": "Female participants will be withdrawn if pregnant",
        "text": "Female participants will be withdrawn from the study if the participant becomes pregnant"
      },
      {
        "id": "cond_8",
        "name": "Enrollment Cap for Women",
        "instanceType": "Condition",
        "description": "Upper limit on female enrollment",
        "text": "An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screening to Randomization Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_treatment",
        "text": "Participants who have no glycemic assessments suggestive of T2DM and meet all other applicable inclusion criteria and none of the applicable exclusion criteria at Visit 1 will continue to Visit 2"
      },
      {
        "id": "trans_2",
        "name": "Visit 1 to Visit 2 Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "visit_1",
        "toElementId": "visit_2",
        "text": "Participants who have no glycemic assessments suggestive of T2DM and meet all other applicable inclusion criteria and none of the applicable exclusion criteria at Visit 1 will continue to Visit 2"
      },
      {
        "id": "trans_3",
        "name": "Week 72 to Additional Treatment Period",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment_72wk",
        "toElementId": "epoch_treatment_additional",
        "text": "Participants classified as having prediabetes at randomization and who remain on study drug through Week 72, will continue follow-up for an additional 104 weeks"
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for GI Symptoms",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If intolerable GI symptoms persist despite the above measures, the investigator should contact Lilly to consider reinitiating study drug at the next-lowest maintenance dose in a blinded fashion (for example, 15 mg reduced to 10 mg, 10 mg reduced to 5 mg, or 5 mg reduced to placebo)"
      },
      {
        "id": "trans_5",
        "name": "Discontinuation for Persistent GI Symptoms",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If intolerable GI symptoms persist despite symptomatic treatment, temporary drug interruption, and resumption at a lower dose of study drug, the participant should be discontinued from study drug"
      },
      {
        "id": "trans_6",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Female participants will be withdrawn from the study if the participant becomes pregnant"
      },
      {
        "id": "trans_7",
        "name": "Dose Escalation Schedule",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Dosing algorithms starting at a low dose of 2.5 mg accompanied by dose escalation of 2.5-mg increments every 4 weeks"
      },
      {
        "id": "trans_8",
        "name": "Treatment to Safety Follow-up (72 weeks)",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_safety_followup",
        "text": "For participants who discontinue or complete the study within the first 72 weeks, Visit 801 (safety follow-up visit) should be performed 4 weeks after the last visit during the 72-week treatment period"
      },
      {
        "id": "trans_9",
        "name": "Treatment to Safety Follow-up (176 weeks)",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment_additional",
        "toElementId": "epoch_safety_followup_extended",
        "text": "For participants with prediabetes who complete the 176 weeks or discontinue after Week 72, Visit 802 should be performed 17 weeks after the last visit during the additional 2-year treatment period"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Early Discontinuation of Treatment",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants unable or unwilling to continue the study treatment for any reason will perform an early discontinuation of treatment (ED) visit"
      },
      {
        "id": "exit_2",
        "name": "Study Completion at 72 Weeks",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of 72-week treatment period for participants without prediabetes"
      },
      {
        "id": "exit_3",
        "name": "Study Completion at 176 Weeks",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of 176-week treatment period for participants with prediabetes at randomization"
      },
      {
        "id": "exit_4",
        "name": "Discontinuation for Pregnancy",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Female participants will be withdrawn from the study if the participant becomes pregnant"
      },
      {
        "id": "exit_5",
        "name": "Discontinuation for Persistent GI Symptoms",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participant should be discontinued from study drug if intolerable GI symptoms persist despite symptomatic treatment, temporary drug interruption, and resumption at a lower dose"
      },
      {
        "id": "exit_6",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participants lost to follow-up as described in Section 7.3"
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Week 72 Prediabetes Continuation Decision",
        "timepointId": "pt_week72",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for participants with prediabetes to continue into additional 2-year treatment period",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "GI Symptom Management Decision",
        "timepointId": "pt_any",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for managing intolerable GI symptoms including temporary interruption and dose reduction",
        "conditionIds": [
          "cond_3",
          "cond_6"
        ]
      },
      {
        "id": "dec_3",
        "name": "Dose Modification for Excessive Weight Loss",
        "timepointId": "pt_week72_to_176",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for dose modification in participants with perceived excessive weight loss during additional 2-year treatment period",
        "conditionIds": [
          "cond_4"
        ]
      },
      {
        "id": "dec_4",
        "name": "Energy Intake Recalculation Decision",
        "timepointId": "pt_any",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point to recalculate energy intake when BMI ≤22 kg/m2 is reached",
        "conditionIds": [
          "cond_5"
        ]
      },
      {
        "id": "dec_5",
        "name": "Missed Dose Decision",
        "timepointId": "pt_any",
        "instanceType": "ScheduledDecisionInstance",
        "description": "If a dose is missed, take as soon as possible unless within 72 hours of next dose, in which case skip the missed dose"
      }
    ],
    "summary": {
      "timingCount": 18,
      "conditionCount": 8,
      "transitionRuleCount": 9,
      "exitCount": 6
    }
  }
}